Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  This Schedule 13G is being filed in accordance with Rule 13d-1(h) to reflect that Tang Capital Management, LLC ("TCM"), Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang (the "Reporting Persons"), no longer hold the securities with a purpose or effect of changing or influencing control of the Issuer. This Schedule 13G is being filed as Amendment No. 2 to the Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on May 22, 2023, as amended on November 27, 2023, with respect to the Issuer's Common Stock of Atea Pharmaceuticals, Inc. (the "Issuer"). TCM shares voting and dispositive power over such shares with TCP, TCPI, TCP III and Kevin Tang. The percentages used herein are based on 80,204,699 Common Stock outstanding as of August 10, 2026, as set forth in the Issuer's Quarterly Report filed on Form 10-Q with the Securities and Exchange Commission on August 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III and TCM.


SCHEDULE 13G




Comment for Type of Reporting Person:  TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person:  TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person:  TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G





SCHEDULE 13G



 
TANG CAPITAL MANAGEMENT, LLC
 
Signature:/s/ Kevin Tang
Name/Title:Manager
Date:10/06/2026
 
KEVIN TANG
 
Signature:/s/ Kevin Tang
Name/Title:Self
Date:10/06/2026
 
TANG CAPITAL PARTNERS, LP
 
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:10/06/2026
 
TANG CAPITAL PARTNERS INTERNATIONAL, LP
 
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:10/06/2026
 
TANG CAPITAL PARTNERS III, INC
 
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:10/06/2026
 
TANG CAPITAL PARTNERS IV, INC
 
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:10/06/2026

 

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Atea Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

 

Date: October 6, 2026 TANG CAPITAL PARTNERS, LP 
     
  By:   Tang Capital Management, LLC    
  Its:   General Partner   
     
  By:   /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Manager   
         
  TANG CAPITAL PARTNERS INTERNATIONAL, LP
   
  By:   Tang Capital Management, LLC    
  Its:   General Partner   
       
  By:   /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Manager   
         
  TANG CAPITAL PARTNERS III, INC 
   
  By:   /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Chief Executive Officer   
         
  TANG CAPITAL PARTNERS IV, INC 
       
  By:   /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Chief Executive Officer   
         
  TANG CAPITAL MANAGEMENT, LLC 
       
  By: /s/ Kevin Tang  
    Name:   Kevin Tang   
    Title:   Manager   
     
  /s/ Kevin Tang  
  Name: Kevin Tang